Eurofins Biopharma Product Testing UK
Pharmaceuticals - , Scotland, United Kingdom
Eurofins Biopharma Product Testing UK Employees
Eurofins Biopharma Product Testing UK Details
Eurofins Biopharma Product Testing UK is a member of the Eurofins network of laboratories. We have 2 facilities, based in Livingston and Portsmouth and offer the following testing services: Livingston- Chemical and microbiological batch release testing of raw materials, drug substance and drug products.- Over 25 years experience in finished product testing, including a wide variety of dosage forms and niche products (eye-drops, transdermal patches, freeze dried injectables, etc.)- Packaging testing- Method development, validation & transfer - Stability storage and testing (ICH conditions zones I to IV)Portsmouth - We perform most industrial microbiological methods but are specialists in the area of disinfectant efficacy testing and the only laboratory in the UK with 15 different European standard test methods for disinfectant efficacy UKAS accredited.Access to the Global Eurofins Biopharmaceutical Product Testing network of 39 facilities in 19 countries deliver the world's most comprehensive scope of harmonised GMP testing services and seamless regulatory acceptance.Our services range from physical, chemical and microbiological testing of pharmaceutical raw materials to finished dosage forms, and we support the complete product development cycle, thereby covering method development and validation, release, stability studies for small and large molecule drug products, and medical devices.Accrediations:-ISO 17025 -ISO 9000-ISO 14001 Eurofins BioPharma Product Testing is part of Eurofins Scientific, global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to 58,000 staff across a network of over 1,000 independent companies in 54 countries, operating 900 laboratories, with a revenue of over EUR 6.7 billion in 2021.
